Cargando…

The Efficacy, Safety, and Satisfaction Associated with Switching from Brinzolamide or Brimonidine to Brinzolamide/Brimonidine in Open-Angle Glaucoma Patients

We evaluated switching from brinzolamide 1% or brimonidine 0.1% to a fixed-combination of brinzolamide 1% and brimonidine 0.1%, and then determined the efficacy, safety, and satisfaction associated with these changes in glaucoma patients. This prospective, nonrandomized study evaluated a total of 31...

Descripción completa

Detalles Bibliográficos
Autores principales:	Onoe, Hiromitsu, Hirooka, Kazuyuki, Nagayama, Mikio, Mochizuki, Hideki, Hirota, Atsushi, Suzuki, Katsuyoshi, Sagara, Takeshi, Kiuchi, Yoshiaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782658/ https://www.ncbi.nlm.nih.gov/pubmed/36556275 http://dx.doi.org/10.3390/jpm12122057

Ejemplares similares

The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients
por: Onoe, Hiromitsu, et al.
Publicado: (2021)

Randomized Trial of Brinzolamide/Brimonidine Versus Brinzolamide Plus Brimonidine for Open-Angle Glaucoma or Ocular Hypertension
por: Gandolfi, Stefano A., et al.
Publicado: (2014)

Brinzolamide/Brimonidine Fixed Combination: Simplifying Glaucoma Treatment Regimens
por: Moosavi, Reza, et al.
Publicado: (2018)

Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension
por: Wang, Ningli, et al.
Publicado: (2020)

Fixed-combination brinzolamide 1%/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies
por: Realini, T, et al.
Publicado: (2013)

Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus
por: Nguyen, Quang H
Publicado: (2014)

Six-month results from a Phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension
por: Whitson, Jess T, et al.
Publicado: (2013)

Ocular Distribution of Brimonidine and Brinzolamide after Topical Instillation of a 0.1% Brimonidine Tartrate and 1% Brinzolamide Fixed-Combination Ophthalmic Suspension: An Interventional Study
por: Orii, Yusuke, et al.
Publicado: (2023)

Evaluation of the Use of Brinzolamide-Brimonidine Fixed Combination in Maximum Medical Therapy
por: Tekeli, Oya, et al.
Publicado: (2022)

Clinical effectiveness of brinzolamide 1%–brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension
por: Sharma, Sourabh, et al.
Publicado: (2015)

Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension
por: Topouzis, Fotis, et al.
Publicado: (2019)

Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension
por: Lerner, S Fabián, et al.
Publicado: (2019)

The effect of a brinzolamide/brimonidine fixed combination on optic nerve head blood flow in rabbits
por: Takahashi, Nana, et al.
Publicado: (2023)

Efficacy and Tolerability of Fixed-Combination Brinzolamide/Timolol in Latin American Patients with Open-Angle Glaucoma or Ocular Hypertension Previously on Brimonidine/Timolol Fixed Combination
por: Alezzandrini, Arturo, et al.
Publicado: (2014)

Efficacy and safety of a fixed combination of 1% brinzolamide and 0.1% brimonidine as treatment for glaucoma: a retrospective study focusing on the number of ingredients
por: Aoki, Ryota, et al.
Publicado: (2022)

Efficacy and tolerability of brinzolamide/brimonidine suspension and prostaglandin analogs in patients previously treated with dorzolamide/timolol solution and prostaglandin analogs
por: Lo, Jonathan S, et al.
Publicado: (2016)

Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial
por: Fechtner, R D, et al.
Publicado: (2016)

Comparative Assessment of Retinal Blood Flow Velocity Changes Following Brimonidine and Brinzolamide Administration Using Retinal Function Imaging
por: Enz, Tim J., et al.
Publicado: (2022)

Safety and efficacy of a fixed versus unfixed brinzolamide/timolol combination in Japanese patients with open-angle glaucoma or ocular hypertension
por: Nagayama, Mikio, et al.
Publicado: (2014)

Brimonidine in the treatment of glaucoma and ocular hypertension
por: Cantor, Louis B
Publicado: (2006)

Evaluation of brimonidine-timolol fixed combination in patients of primary open-angle glaucoma
por: Joshi, Sachin R, et al.
Publicado: (2013)

Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension
por: Syed, Misha F, et al.
Publicado: (2011)

Effects of the Glaucoma Drugs Latanoprost and Brimonidine on Corneal Temperature
por: Konieczka, Katarzyna, et al.
Publicado: (2019)

The Effect of Brimonidine 0.1% on Disc Hemorrhage in Primary Open-Angle Glaucoma Patients
por: Nitta, Koji, et al.
Publicado: (2020)

Crossover Randomized Study of Pharmacologic Effects of Ripasudil–Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine
por: Tanihara, Hidenobu, et al.
Publicado: (2023)

Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension
por: Iester, Michele
Publicado: (2008)

Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost
por: Imasawa, Mitsuhiro, et al.
Publicado: (2016)

Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension
por: Yoshikawa, Keiji, et al.
Publicado: (2014)

Brinzolamide-timolol suspension: acceptability and side effect profile
por: Doherty, MD, et al.
Publicado: (2011)

Crystal structure of Brinzolamide: a carbonic anhydrase inhibitor
por: Zheng, Huirong, et al.
Publicado: (2016)

Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
por: Galanopoulos, Anna, et al.
Publicado: (2009)

Brimonidine prevents neurodegeneration in a mouse model of normal tension glaucoma
por: Semba, K, et al.
Publicado: (2014)

Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/timolol among patients with open-angle glaucoma or ocular hypertension
por: Sanseau, Ana, et al.
Publicado: (2013)

Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension [Erratum]
Publicado: (2014)

24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost
por: Nakamura, Yoshimi, et al.
Publicado: (2009)

Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy
por: Li, Tingting, et al.
Publicado: (2020)

Patient perspectives when switching from Cosopt(®) (dorzolamide-timolol) to Azarga™ (brinzolamide-timolol) for glaucoma requiring multiple drug therapy
por: Auger, Graham Anthony, et al.
Publicado: (2012)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
por: Baiza-Durán, Leopoldo Martín, et al.
Publicado: (2012)

Comparison of surgical outcomes between iStent inject W implantation and microhook ab interno trabeculotomy in combination with phacoemulsification in primary open-angle glaucoma patients
por: Onoe, Hiromitsu, et al.
Publicado: (2023)

Formulation Development and Evaluation of the Therapeutic Efficacy of Brinzolamide Containing Nanoemulsions
por: Mahboobian, Mohammad Mehdi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_l5uhuoio11ovsct23514g0pc25